MedTrace Logo

Trial to Assess Chelation Therapy (TACT)

NCT00044213 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1708

Last updated 2013-11-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease.

Conditions

Interventions

DRUG

EDTA

Participants will receive 40 infusions of standard chelation solution.

DRUG

EDTA Placebo

Participants will receive 40 infusions of EDTA placebo.

DIETARY_SUPPLEMENT

High Dose Vitamin

DIETARY_SUPPLEMENT

High Dose Vitamin Placebo

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Mt. Sinai Medical Center, Miami

    lead OTHER

Principal Investigators

  • Gervasio A Lamas, M.D. · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2011-10-31
Completion
2012-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044213 on ClinicalTrials.gov